Genome wide analysis and comparative docking studies of new diaryl furan derivatives against human cyclooxygenase-2, lipoxygenase, thromboxane synthase and prostacyclin synthase enzymes involved in inflammatory pathway

Journal of Molecular Graphics & Modelling
P Nataraj SekharP B Kavi Kishor


In an effort to develop potent anti-inflammatory and antithrombotic drugs, a series of new 4-(2-phenyltetrahydrofuran-3-yl) benzene sulfonamide analogs were designed and docked against homology models of human cyclooxygenase-2 (COX-2), lipoxygenase and thromboxane synthase enzymes built using MODELLER 7v7 software and refined by molecular dynamics for 2 ns in a solvated layer. Validation of these homology models by procheck, verify-3D and ERRAT programs revealed that these models are highly reliable. Docking studies of 4-(2-phenyltetrahydrofuran-3-yl) benzene sulfonamide analogs designed by substituting different chemical groups on benzene rings replacing 1H pyrazole in celecoxib with five membered thiophene, furan, 1H pyrrole, 1H imidazole, thiazole and 1,3-oxazole showed that diaryl furan molecules showed good binding affinity towards mouse COX-2. Further, docking studies of diaryl furan derivatives are likely to have superior thromboxane synthase and COX-2 selectivity. Docking studies against site directed mutagenesis of Arg120Ala, Ser530Ala, Ser530Met and Tyr355Phe enzymes displayed the effect of inhibition of COX-2. Drug likeliness and activity decay for these inhibitors showed that these molecules act as best drugs at ver...Continue Reading


Mar 5, 1992·Nature·R LüthyD Eisenberg
Oct 5, 1990·Journal of Molecular Biology·S F AltschulD J Lipman
Mar 1, 1970·Journal of Molecular Biology·S B Needleman, C D Wunsch
Dec 15, 1994·Nature·C A OrengoJ M Thornton
Dec 5, 1993·Journal of Molecular Biology·A Sali, T L Blundell
May 23, 1996·Nature·R W HooftE E Abola
Aug 1, 1996·Current Opinion in Biotechnology·B Rost, A Valencia
Oct 1, 1997·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Y Xu, E C Uberbacher
Oct 7, 1998·Protein Science : a Publication of the Protein Society·J LiangC Woodward
Apr 9, 1999·Protein Engineering·B Rost
Apr 26, 2000·Genome Research·A A Salamov, V V Solovyev
Dec 5, 2000·Prostaglandins & Other Lipid Mediators·L Iversen, K Kragballe
Apr 12, 2001·Journal of Medicinal Chemistry·M Stahl, M Rarey
Feb 22, 2002·Journal of Cellular Physiology·Yang Cao, Stephen M Prescott
Sep 21, 2002·Proceedings of the National Academy of Sciences of the United States of America·N V ChandrasekharanDaniel L Simmons
Feb 13, 2003·Biopolymers·Mark R McGannFrank K Brown
Oct 6, 2006·Journal of Molecular Biology·Chia-Wang ChiangNei-Li Chan


Mar 4, 2011·Interdisciplinary Sciences, Computational Life Sciences·Amineni UmamaheswariHemanthkumar Marisetty

Related Concepts

Prostacyclin synthase
PTGS1 protein, human
Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human
Cytochrome P-450 Oxygenase
Thromboxane-A Synthase

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.